Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-26
2011-07-26
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S267000
Reexamination Certificate
active
07985745
ABSTRACT:
This invention discloses a method of treating pain by administering histamine H4receptor ligands and compositions comprising the same.
REFERENCES:
patent: 3755583 (1973-08-01), De Angelis et al.
patent: 5071999 (1991-12-01), Schenke et al.
patent: 6204017 (2001-03-01), Behan et al.
patent: 6803362 (2004-10-01), Carruthers et al.
patent: 2003/0207893 (2003-11-01), Carruthers et al.
patent: 2004/0048878 (2004-03-01), Cai et al.
patent: 2005/0070527 (2005-03-01), Edwards et al.
patent: 2005/0070550 (2005-03-01), Arienti et al.
patent: 2005/0101602 (2005-05-01), Basha et al.
patent: 2006/0025614 (2006-02-01), Carroll et al.
patent: 2006/0100194 (2006-05-01), Blackburn et al.
patent: 2006/0111416 (2006-05-01), Lane et al.
patent: 2007/0149541 (2007-06-01), Buzard et al.
patent: 2007/0185075 (2007-08-01), Bell et al.
patent: 2007/0185131 (2007-08-01), Cai et al.
patent: 2008/0188452 (2008-08-01), Altenbach et al.
patent: 1767537 (2007-03-01), None
patent: 2221262 (1990-09-01), None
patent: 1994220059 (1993-01-01), None
patent: WO9507893 (1995-03-01), None
patent: 0162233 (2001-08-01), None
patent: 02/072548 (2002-09-01), None
patent: 02072548 (2002-09-01), None
patent: 03020907 (2003-03-01), None
patent: 2004022061 (2004-03-01), None
patent: 2004066960 (2004-08-01), None
patent: 2005007648 (2005-01-01), None
patent: 2005/014556 (2005-02-01), None
patent: 2005014556 (2005-02-01), None
patent: 2005014579 (2005-02-01), None
patent: WO2005037825 (2005-04-01), None
patent: WO2005042500 (2005-05-01), None
patent: 2005/054239 (2005-06-01), None
patent: 2005054239 (2005-06-01), None
patent: 2005092066 (2005-10-01), None
patent: WO2006041773 (2006-04-01), None
patent: 2006/050965 (2006-05-01), None
patent: 2006050965 (2006-05-01), None
patent: WO2006050965 (2006-05-01), None
patent: 2007090852 (2007-02-01), None
patent: 2007072163 (2007-06-01), None
patent: 2007/090852 (2007-08-01), None
patent: 2007090853 (2007-08-01), None
patent: 2007090854 (2007-08-01), None
patent: WO2007090852 (2007-08-01), None
patent: 2008031556 (2008-03-01), None
Adami, M., Anti-inflammatory, Analgesic and Gastroprotective Effects of the Histamine H-4 Receptor Antagonist May 2005 Poster Session: Histamine Receptors, p. 47.
Akdis,, Cezmi and Simons, Estelle, “Histamine receptors are hot in immunopharmacology”, European Journal of Pharmacology, vol. 533; pp. 69-76; (2006).
Collins, Susanne and Chessell, Iain, “Emerging therapies for neuropathic pain”, Expert Opin. Emerging Drugs. vol. 10(1); pp. 95-108, (2005).
Coruzzi, Gabriella, et al., “Anti-inflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation”, European Journal of Pharmacology. vol. 563, pp. 240-244 (2007).
de Esch, Iwan, et al. “The histamine H4receptor as a new therapeutic target for inflammation”, Trends in Pharmacological Sciences. vol. 26 No. 9; pp. 462-469 (2005).
Dworkin, Robert H., “An overview of Neuropathic Pain: Syndromes, Symptoms, Sign, and Several Mechanisms”, Clinical Journal of Pain. vol. 18: 343-349 (2002).
Joshi, Shailen and Honore, Prisca, “Animal models of pain for drug discovery”, Expert Opin. Drug Discov, vol. 1(4); pp. 323-334, (2006).
Smith, Peter A.. “Neuropathic Pain: Drug Targets for Current and Future Interventions” Drugs News Perspect 17(1), pp. 5-17; (2004).
Zhang, Mai et al.; “The histamine H4receptor in autoimmune disease”, Expert Opin. Investig. Drugs. vol. 15(11); pp. 1443-1452 (2006).
Bennett and Xie, “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man”, Pain 33: 87-107 (1988).
Chaplan et al., “Quantitative assessment of tactile allodynia in the rat paw”, J. Neuroscience Methods, 53: 55-63 (1994).
Coge, et al., “Structure and Expression of the Human Histamine H4-Receptor Gene”, Biochemical and Biophysical Research Communications, 284: 301-309 (2001).
Collins, et al., “Emerging therapies for neuropathic pain”, Expert Opinion on Emerging Drugs, 10(1): 95-108 (2005).
De Esch, et al., “The histamine H4 Receptor as a new therapeutic target for inflammation”, Trends in Pharmacological Science, 26: 462-469 (2005).
Dixon, “Efficient Analysis of Experimental Observations”, Annual Rev. Pharmacol. Toxicol., 20: 441-462 (1980).
Dray, et al., “Pharmacology of chronic pain”, Trends in Pharmacological Sciences, 15(6): 190-197 (1994).
Dworkin, R., “An Overview of Neuropathic Pain: Syndromes, Symptons, Signs, and Several Mechanisms”, Clinical Journal of Pain, 18(6): 343-349 (2002).
Esbenshade, et al., “Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist”, Biochemical Pharmacology, 68: 933-945 (2004).
Furniss, et al., “Vogel's Textbook of Practical Organic Chemistry”, 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England (Table of Contents).
Hartwig, “Transition Metal Catalyzed Synthesis of Arylamines and Aryl Ethers from Aryl Halides and Triflates: Scope and Mechanism”, Angew. Chem. Int. Ed., 37:2046-2067 (1998).
Hartwig, et al. “Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chloride and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand”, J. Org. Chem., 64(15):5575-5580 (1999).
Honore, et al., “Interleukin-1 alpha beta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain”, Behavioural Brain Research, 167: 355-364 (2006).
Hough, “Genomics Meets Histamine Receptors: New Subtypes, New Receptors”, Molecular Pharmacology, 59: 415-419 (2001).
Higuchi et al., Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series (Table of Contents), (1975).
Igaz, et al., Histamine: Biology and Medical Aspects, 89-96 (2004).
IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 45: 13-30 (1976).
Jablonowski, et al., “The First Potent and Selective Non-Imidazole Human Histamine H4 Receptor Antagonists”, Journal of Medicinal Chemistry, 46: 3957-3960 (2003).
Joshi et al., “Animal models of pain for drug discovery”, Expert Opinion in Drug Discovery, 1: 323-334 (2004).
Joshi, et al., “Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states”, Pain, 123: 75-82 (2006).
Kim, et al., “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat”, Pain, 50: 355-363 (1992).
Kiyomori et al., “An Efficient Copper-Catalyzed Coupling of Aryl Halides with Imidazoles”, Tet. Lett., 40:2657-2640 (1999).
Klapars et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles”, J. Amer. Chem. Soc., 123:7727-7729 (2001).
Krueger, et al., “G Protein-Dependent Pharmacology of Histamine H3 Receptor Ligands: Evidence for Heterogeneous Active State Receptor Conformations”, Journal of Pharmacology and Experimental Therapeutics, 314: 271-281 (2005).
Kwong et al., “Copper-Catalyst Coupling of Alkylamines and Aryl Iodides: An Efficient System Even in an Air Atmosphere”, Org. Lett., 4:581-584 (2002).
Ling, et al., “Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation”, British Journal of Pharmacology, 142: 161-171 (2004).
Liu, et al., “Comparison of Human, Mouse, Rat, and Guinea Pig Histamine H4 Receptors Reveals Substantial Pharmacological Species Variation”, Journal of Pharmacology and Experimental Therapeutics, 299: 121-130 (2001).
Liu, et al., “Cloning and Pharmacological Characterization of
Altenbach Robert J.
Babinski David J.
Black Lawrence A.
Brioni Jorge D.
Cowart Marlon D.
Abbott Laboratories
Chen Portia
Ferrari-Dileo Gabryleda
Gettel Nancy J.
Javanmard Sahar
LandOfFree
Method for pain treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for pain treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for pain treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2646743